Researchers have developed a new method to combat drug-resistant cancers by utilizing the mutations that cause resistance. A computational tool, SpotNeoMet, identifies common mutations that create neo-antigens, which can then be targeted by the immune system. This approach, tested on metastatic prostate cancer, aims to create broad immunotherapy treatments for large patient groups, potentially changing how treatment-resistant cancers are approached.